HBEGF and cancer: The antineoplastic activity of CRM197 was investigated in a number of studies, which showed the potential of this HBEGF inhibitor, mainly in increasing the activity of commonly used anticancer drugs, such as cisplatin, doxorubicin and paclitaxel, in cultured human cancer cells from different neoplastic conditions [76,77]; in some models, reversion of drug resistance was also observed [78,79].